FUM — Futura Medical Share Price
Last trade - 00:00- £28.40m
- £21.80m
- £13.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.17 | ||
| Price to Tang. Book | 3.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.04 | ||
| EV to EBITDA | 15.96 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.76% | ||
| Return on Equity | 17.91% | ||
| Operating Margin | 8.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 3.1 | 13.93 | 5.04 | 5.1 | 237.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.
Directors
- John Clarke NEC (71)
- James Barder CEO (58)
- Angela Hildreth FID
- Ken James EDR (66)
- Jeffrey Needham NED (65)
- Andrew Unitt NED (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 25th, 2001
- Public Since
- July 10th, 2006
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 303,703,568
- Address
- 40 Occam Road, GUILDFORD, GU2 7YG
- Web
- https://www.futuramedical.com/
- Phone
- +44 1483685670
- Auditors
- Grant Thornton UK LLP
Latest News for FUM
Upcoming Events for FUM
Half Year 2025 Futura Medical PLC Earnings Release
Similar to FUM
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 20:44 UTC, shares in Futura Medical are trading at 9.35p. This share price information is delayed by 15 minutes.
Shares in Futura Medical last closed at 9.35p and the price had moved by -72.5% over the past 365 days. In terms of relative price strength the Futura Medical share price has underperformed the FTSE All Share Index by -75.14% over the past year.
The overall consensus recommendation for Futura Medical is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreFutura Medical does not currently pay a dividend.
Futura Medical does not currently pay a dividend.
Futura Medical does not currently pay a dividend.
To buy shares in Futura Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 9.35p, shares in Futura Medical had a market capitalisation of £28.40m.
Here are the trading details for Futura Medical:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: FUM
Based on an overall assessment of its quality, value and momentum Futura Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Futura Medical is 30.00p. That is 220.86% above the last closing price of 9.35p.
Analysts covering Futura Medical currently have a consensus Earnings Per Share (EPS) forecast of -£0.01 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Futura Medical. Over the past six months, its share price has underperformed the FTSE All Share Index by -32.82%.
As of the last closing price of 9.35p, shares in Futura Medical were trading -49.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Futura Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 9.35p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Futura Medical's management team is headed by:
- John Clarke - NEC
- James Barder - CEO
- Angela Hildreth - FID
- Ken James - EDR
- Jeffrey Needham - NED
- Andrew Unitt - NED